



GLOBAL STATUS REPORT ON BLOOD SAFETY AND AVAILABILITY 2021



**World Health
Organization**

GLOBAL STATUS REPORT ON BLOOD SAFETY AND AVAILABILITY 2021



**World Health
Organization**

Global status report on blood safety and availability 2021

ISBN 978-92-4-005168-3 (electronic version)

ISBN 978-92-4-005169-0 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Global status report on blood safety and availability 2021. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

| | |
|--|-------------|
| Preface | vii |
| Acknowledgements | viii |
| Abbreviations | ix |
| Chapter 1. Introduction | 1 |
| Chapter 2. Organization and management of national blood transfusion services | 3 |
| 2.1 Policy and governance | 3 |
| 2.2 Finance | 5 |
| 2.3 Inspection and licensing | 6 |
| Chapter 3. Collection of blood and blood components | 8 |
| 3.1 Global overview of blood collection | 8 |
| 3.2 Whole blood collection and apheresis collection | 10 |
| 3.3 Types of blood donations | 11 |
| 3.4 Trends in whole blood collections in the world, 2008–2018 | 13 |
| 3.5 Blood donor profile | 16 |
| 3.5.1 Donor sex and age profile | 16 |
| 3.5.2 Repeat donors and first-time donors | 18 |
| 3.5.3 Donor deferral | 19 |
| Chapter 4. Processing of whole blood donations into components | 21 |
| Chapter 5. Laboratory screening of blood donations | 23 |
| 5.1 Laboratory screening policy | 23 |
| 5.1.1 Human immunodeficiency virus, hepatitis B virus, and hepatitis C virus | 23 |
| 5.1.2 Syphilis | 24 |
| 5.1.3 Chagas | 25 |
| 5.1.4 Human T-lymphotropic virus | 25 |
| 5.1.5 Malaria | 26 |
| 5.1.6 Other transfusion-transmissible infections | 27 |
| 5.2 Coverage and quality of laboratory screening of blood donations | 28 |
| 5.3 Prevalence of markers of infection in blood donations | 29 |
| Chapter 6. Discard of blood | 31 |
| Chapter 7. Clinical use of blood | 33 |
| 7.1 Assessing the need and demand for blood | 33 |
| 7.2 Patients who received blood transfusion | 35 |
| 7.3 Blood and blood components transfused | 37 |

| | | |
|---|--|-----------|
| 7.4 | Change in blood and blood components transfusion between 2013 and 2018 | 40 |
| 7.5 | Strategies to improve evidence-based transfusion practice and monitor safe and appropriate blood transfusion | 42 |
| 7.6 | The risks of undertransfusion: unmet demand for blood in resource-limited countries | 43 |
| Chapter 8. Haemovigilance | | 44 |
| Chapter 9. Plasma used for fractionation and the provision of plasma-derived medicinal products | | 47 |
| Chapter 10. Discussion and conclusions | | 49 |
| 10.1 | Blood availability | 49 |
| 10.2 | Blood safety | 50 |
| 10.3 | Clinical transfusion practice | 50 |
| 10.4 | Data | 51 |
| 10.5 | Conclusions | 51 |
| Chapter 11. Limitations | | 53 |
| References | | 54 |
| Annexes | | 57 |
| Annex 1. Explanatory note on country data and methodology. | | 58 |
| Annex 2. Blood centres and data coverage, 2014/2018 | | 61 |
| Annex 3. Blood donations, 2014/2018. | | 80 |
| Annex 4. Laboratory test requirements for screening donated blood for transfusion-transmissible infections, 2017/2018 | | 107 |
| Annex 5. Number and proportion of donations tested positive/reactive for TTI markers, 2014/2018 | | 112 |
| Annex 6. Clinical use of blood and blood components, 2014/2018 | | 137 |
| Annex 7. Provision of plasma-derived medicinal products (PDMPs) through the fractionation of plasma collected in the country, 2014/2018 | | 156 |
| Annex 8. Policy, governance, quality assurance and monitoring, 2017/2018 | | 162 |



Figures

| | |
|---|----|
| Figure 1. Governance mechanisms for blood transfusion by WHO region, 2018. | 4 |
| Figure 2. Systems of blood service financing | 5 |
| Figure 3. Distribution (percentage) of population and blood donations by WHO region and World Bank income group, 2018. | 9 |
| Figure 4. Distribution of countries by number of whole blood donations per 1000 population, 2018 | 9 |
| Figure 5. Whole blood donations per 1000 population, 2018. | 10 |
| Figure 6. Method of collection of blood donations by WHO region and World Bank income group, 2018 | 10 |
| Figure 7. Proportions of voluntary non-remunerated whole blood donations by WHO region and World Bank income group, 2018 | 11 |
| Figure 8. Total number of apheresis donations (thousands) and distribution of donation types by WHO region. | 12 |
| Figure 9. Proportion of voluntary non-remunerated donations (whole blood and apheresis donations combined) by country, 2018 | 12 |
| Figure 10. Total whole blood collections and voluntary non-remunerated donations (millions) by WHO region, 2008–2018 | 14 |
| Figure 11. Contributions to donations by donors of different age groups in selected countries, 2018. | 17 |
| Figure 12. Contribution to donations by donors of different age groups and by World Bank income group, 2018 | 18 |
| Figure 13. Donor deferral rate (%) by reason in countries in different income groups | 19 |
| Figure 14. Whole blood donations processed into components by WHO region and World Bank income group, 2018 (%) | 21 |
| Figure 15. Distribution of discards of blood donations by reason, 2018. | 31 |
| Figure 16. Paradigm of need for, demand for, and use of blood | 34 |
| Figure 17. Age distribution of patients who received transfusion in selected countries | 36 |
| Figure 18. Distribution of blood units transfused in different clinical departments in selected countries in Africa | 37 |
| Figure 19. Distribution of countries reporting the existence of national haemovigilance systems, 2018. | 45 |
| Figure 20. Serious adverse transfusion reactions reported | 46 |

Tables

| | |
|---|----|
| Table 1. Policy and governance results: responses by countries, 2018 | 3 |
| Table 2. Funding models for responding countries | 5 |
| Table 3. International financial and technical support | 6 |
| Table 4. Total funding per collection by World Bank economic group, 2018 | 6 |
| Table 5. Inspection and licensing results for responding countries | 7 |
| Table 6. Estimated blood donations by WHO region, 2018 | 8 |
| Table 7. Voluntary non-remunerated donation (VNRD) and total whole blood collection in 119 countries (millions) by WHO region, 2008–2018 | 14 |
| Table 8. Annual rate of change of whole blood collections (total and voluntary non-remunerated donation, VNRD) by WHO region, 2008–2018 (median and range, %) | 15 |
| Table 9. Blood donations from female donors by WHO region (median and range, %) | 16 |
| Table 10. Donations given by repeat voluntary non-remunerated blood donors by WHO region (median and range, %) | 19 |
| Table 11. Donor deferral rate by WHO region (median and interquartile range, %) | 20 |
| Table 12. Proportion of blood donations processed into components: number of countries in each percentage grouping by WHO region, 2018 | 22 |
| Table 13. Distribution of blood laboratory screening policies for HIV-1/2 by WHO region | 24 |
| Table 14. Distribution of blood laboratory screening policies for HBV by WHO region. | 24 |

| | |
|---|----|
| Table 15. Distribution of blood laboratory screening policies for HCV by WHO region | 24 |
| Table 16. Testing for Chagas disease | 25 |
| Table 17. Testing for HTLV-1/2 | 26 |
| Table 18. Malaria testing policy in 51 countries | 27 |
| Table 19. Proportion of blood screening laboratories that participate in EQAS for testing of TTIs by World Bank income group | 29 |
| Table 20. Proportions of blood donations with positive/reactive results on screening tests by income group | 30 |
| Table 21. Percentage (median and interquartile range) of total whole blood donations discarded by World Bank income group | 32 |
| Table 22. Percentage (median and range) of donations discarded due to reactivity for markers of TTIs by World Bank income group | 32 |
| Table 23. Populations, blood donations and transfusion of blood products in 135 countries by World Bank income group | 38 |
| Table 24. Units of red cell products transfused per 1000 population by World Bank income group | 38 |
| Table 25. Proportion (median and interquartile range, %) of whole blood transfusions among all red cell transfusions by World Bank income group | 39 |
| Table 26. Units of platelet transfused per 1000 population by World Bank income group | 39 |
| Table 27. Units of plasma transfused per 1000 population by World Bank income group | 40 |
| Table 28. Units (millions) of red cell products transfused by WHO region, 2013 and 2018 | 40 |
| Table 29. Units (thousands) of platelets transfused by WHO region, 2013 and 2018 | 41 |
| Table 30. Units (thousands) of plasma products transfused by WHO region, 2013 and 2018 | 41 |
| Table 31. Incidence of serious adverse reaction (per 100 000 units of components transfused) by WHO region | 46 |
| Table 32. Volume (litres) of plasma for fractionation by collection method and WHO region, 2018 | 48 |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31299

